Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

NeuroPace (NPCE) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for NeuroPace (NPCE) over the last 6 years, with Q3 2025 value amounting to 9.51%.

  • NeuroPace's EBITDA Margin rose 106400.0% to 9.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.21%, marking a year-over-year increase of 159500.0%. This contributed to the annual value of 27.12% for FY2024, which is 232500.0% up from last year.
  • Latest data reveals that NeuroPace reported EBITDA Margin of 9.51% as of Q3 2025, which was up 106400.0% from 29.01% recorded in Q2 2025.
  • NeuroPace's EBITDA Margin's 5-year high stood at 9.51% during Q3 2025, with a 5-year trough of 129.01% in Q2 2022.
  • For the 5-year period, NeuroPace's EBITDA Margin averaged around 60.12%, with its median value being 55.26% (2023).
  • Per our database at Business Quant, NeuroPace's EBITDA Margin crashed by -615800bps in 2022 and then skyrocketed by 737500bps in 2023.
  • Over the past 5 years, NeuroPace's EBITDA Margin (Quarter) stood at 100.01% in 2021, then grew by 15bps to 85.39% in 2022, then skyrocketed by 60bps to 34.42% in 2023, then surged by 51bps to 17.02% in 2024, then soared by 44bps to 9.51% in 2025.
  • Its EBITDA Margin stands at 9.51% for Q3 2025, versus 29.01% for Q2 2025 and 22.85% for Q1 2025.